Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Contenido archivado el 2024-06-18

Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuria

Objetivo

Patients with diabetes are at risk of developing diabetic nephropathy, which will ultimately result in the requirement for renal replacement therapy and is also associated with high cardiovascular morbidity and mortality. Detection of low concentrations of albuminuria in urine (microalbuminuria) is the current clinical standard for detecting those at significant risk and targeting preventive treatment. However, albuminuria is of low specificity at early stages of disease, and of considerable biological variability, hence a poor predictor at early stages of disease. In two independent studies we have demonstrated that urinary proteomics offers the prospect of detecting nephropathy earlier in the preclinical phase, enabling targeted treatment at an earlier stage. We propose to assess the potential of this technology to identify normoalbuminuric patients at risk and to target therapy with an aldosterone receptor antagonist (spironolactone) as add-on to recommended therapy including angiotensin converting enzyme (ACE) inhibition or angiotensin II receptor blockers (ARBs) according to national guidelines. We will test the following hypotheses: (1) urinary proteomics predicts progression of albuminuria (as a surrogate marker for the development of overt nephropathy) in a cohort of 3280 type 2 diabetic patients with normal urinary albumin excretion, and (2) early initiation of intensive preventive therapy directed by urinary proteomics reduces progression of albuminuria in those 20 % at high risk and thereby delay progression to overt nephropathy and spare treatment for those with low risk, paving the way of personalised medicine. This will be the first biomarker-directed therapy trial for primary prevention of diabetic kidney disease. Additional clinical and circulating biomarkers will be assessed and models to predict progression of albuminuria including clinical factors, biomarkers and proteomics will be developed.

Ámbito científico

Programa(s)

Tema(s)

Convocatoria de propuestas

FP7-HEALTH-2011-two-stage
Consulte otros proyectos de esta convocatoria

Régimen de financiación

CP-FP - Small or medium-scale focused research project

Coordinador

REGION HOVEDSTADEN
Aportación de la UE
€ 438 930,70
Dirección
KONGENS VAENGE 2
3400 Hillerod
Dinamarca

Ver en el mapa
Región
Danmark Hovedstaden Nordsjælland
Tipo de actividad
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Contacto administrativo
Maria Athena Campbell (Mrs.)
Enlaces
Coste total
Sin datos

Participantes (21)

Compartir esta página

Descargar

Última actualización: 15 Febrero 2022

Mi folleto

Permalink: https://cordis.europa.eu/project/id/279277/es

European Union, 2024